<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526445</url>
  </required_header>
  <id_info>
    <org_study_id>H-18003696</org_study_id>
    <nct_id>NCT03526445</nct_id>
  </id_info>
  <brief_title>Hepatic Metabolic Changes in Response to Glucagon Infusion</brief_title>
  <official_title>Hepatic Metabolic Changes in Response to Glucagon Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate how exogenously administered glucagon affects
      hepatic lipid, glucose and protein metabolism as well as appetite, food intake and resting
      energy expenditure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most research has focused on the role of the pancreatic hormone, insulin, and insulin
      signalling (or lack of) in the development of NAFLD. However, increasing evidence suggest
      that the other major gluco-regulatory pancreatic hormone glucagon is also implicated in lipid
      metabolism and recent human data from studies investigating the effect of glucagon receptor
      antagonism suggest that glucagon signalling may be essential for maintaining a fat-free
      liver. This, combined with our recent observation of increased degree of hepatic steatosis in
      totally pancreatectomised patients, who are devoid of pancreatic glucagon and typically are
      lean and peripherally insulin sensitive, suggests that glucagon may play a hitherto
      unrecognised role in the pathophysiology of NAFLD.

      We hypothesise that exogenously delivered glucagon will drive hepatic metabolism in a
      lipolytic direction and increase resting energy expenditure without affecting appetite and
      food intake. To evaluate the effect of exogenous glucagon in different physiological
      conditions we will include totally pancreatectomised patients (no endogenous pancreatic
      hormones), patients with type 1 diabetes (no endogenous insulin production) and healthy
      controls (preserved endogenous pancreatic hormones).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic lipid metabolism</measure>
    <time_frame>-120,-90,-60,-30,-15,0,30,60,90,120,135,150,180 min</time_frame>
    <description>evaluated using isotopic labelled tracer kinetics: lipolysis, ketogenesis, very low-density lipoprotein (VLDL) secretion and free fatty acid (FFA) re-esterification rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of lipids</measure>
    <time_frame>-120,0,150 min</time_frame>
    <description>Total cholesterol, VLDL, LDL, HDL, FFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of amino acids</measure>
    <time_frame>-120,0,150 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of fibroblast growth factor 21 (FGF-21)</measure>
    <time_frame>-120,0,150 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>-120,-90,-60,-30,-15,0,30,60,90,120,135,150,180 min</time_frame>
    <description>Measured by glucose tracer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in resting energy expenditure and oxidation rate</measure>
    <time_frame>0, 150 min</time_frame>
    <description>Measured by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fat content and stiffness</measure>
    <time_frame>0, 150 min</time_frame>
    <description>Fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food intake</measure>
    <time_frame>30 minutes (150-180) min</time_frame>
    <description>Ad libitum meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in appetite sensation</measure>
    <time_frame>-120,-90,-60,-30,0,30,60,90,120,150,180 min</time_frame>
    <description>Visual analogue scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Total Pancreatectomy</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Glucagon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 hours i.v. infusion of Glucagon (4 ng/kg/min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 hours i.v. infusion of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Glucagon (4 ng/kg/min)</description>
    <arm_group_label>Glucagon</arm_group_label>
    <other_name>GlucaGen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pancreatectomised patients

          -  Patients who have undergone total pancreatectomy

          -  Caucasian between 30-80

          -  Blood haemoglobin &gt;7.0 mmol/l for males and &gt;6.5 mmol/l for females

          -  Informed consent

        Patients with type 1 diabetes

          -  Patients with C-peptide negative type 1 diabetes

          -  Caucasian between 30-80

          -  Blood haemoglobin &gt;7.0 mmol/l for males and &gt;6.5 mmol/l for females

          -  Informed consent

        Healthy controls

          -  Normal fasting plasma glucose (&lt; 7 mmol/l) and normal HbA1c (&lt; 6.5 %) (30,31)

          -  Normal blood haemoglobin (&gt;8.3 mmol/l for males and &gt;7.3 mmol/l for females)

          -  Caucasian between 30-80

          -  Informed consent

        Exclusion Criteria:

        All subjects

          -  Inflammatory bowel disease

          -  Gastrointestinal resection (other than the gastro-duodenectomy performed in connection
             with total pancreatectomy) and/or ostomy

          -  Nephropathy (eGFR &lt; 60 ml/min/1.73 mÂ² and/or urine albumin &gt; 20 mg/L)

          -  Known liver disease (excluding non-alcoholic fatty liver disease)

          -  Severe lung disease

          -  Pregnancy and/or breastfeeding

          -  Uncontrolled hypertension and/or significant cardiovascular disease

          -  Treatment with drugs with potential steatogenic side-effects within three months prior
             to inclusion

          -  Alcohol consumption above 21 units/week for men and 14 units/week for women

          -  Any condition that the investigator feels would interfere with the safety of the trial
             participation or the safety of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip Krag Knop, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iben Rix Petersen, MD</last_name>
    <phone>+45 24917125</phone>
    <email>iben.rix.petersen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iben Rix Petersen, MD</last_name>
      <phone>+45 24917125</phone>
      <email>iben.rix.petersen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucagon</keyword>
  <keyword>Stable isotope</keyword>
  <keyword>Energy expenditure</keyword>
  <keyword>Lipid metabolism</keyword>
  <keyword>Glucose metabolism</keyword>
  <keyword>Appetite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

